Oxaliplatin: Clinical Trials

1,909 trials of Oxaliplatin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

757 completed, 351 unknown, 290 recruiting, 196 terminated. 1262 Phase 2, 391 Phase 1, 383 Phase 3, 47 Not applicable, 25 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21262Completed 492, Unknown 237, Recruiting 183, Terminated 140, Not yet recruiting 82, Active not recruiting 73, Withdrawn 50, Suspended 3, Enrolling by invitation 2
Phase 1391Completed 187, Recruiting 60, Terminated 54, Unknown 38, Active not recruiting 26, Withdrawn 14, Not yet recruiting 11, Suspended 1
Phase 3383Completed 126, Unknown 77, Recruiting 74, Active not recruiting 42, Not yet recruiting 31, Terminated 23, Withdrawn 8, Suspended 2
Not applicable47Completed 14, Unknown 13, Recruiting 10, Not yet recruiting 5, Terminated 4, Enrolling by invitation 1
Phase 425Unknown 10, Completed 6, Not yet recruiting 5, Recruiting 2, Suspended 1, Terminated 1
Early Phase 111Completed 5, Terminated 3, Active not recruiting 1, Enrolling by invitation 1, Unknown 1

Follow Oxaliplatin: new trials by email Literature Review of Oxaliplatin trials Research Report on Oxaliplatin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 3Not yet recruitingTranscenta Therapeutics (Hangzhou) Co., Ltd.8202027-06-302026-09-29
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma
Phase 3Not yet recruitingCStone Pharmaceuticals1502027-06-012026-05-27
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Phase 2Not yet recruitingAbramson Cancer Center at Penn Medicine342027-04-012026-11-04
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.6002027-02-012026-09-14
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor
Phase 3Not yet recruitingGuangdong Provincial People's Hospital1482027-01-012026-07-07
Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma
Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC - Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis
Phase 2Not yet recruitingFujian Cancer Hospital422026-12-152026-10-29
QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients
Intervention 1 - Drug QL1706 (Iparomlimab and Tuvonralimab) Intervention 2 - Drug Lenvatinib Intervention 3 - Drug FOLFOX Chemotherapy (Oxaliplatin, Fluorouracil, and Levoleucovorin Calcium) - Hepatocellular Carcinoma (HCC)
Phase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University332026-12-012026-11-12
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Phase 4Not yet recruitingAstellas Pharma Global Development, Inc.502026-11-302026-09-21
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer
Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma
Phase 3Not yet recruitingZhai Wenlong902026-11-302026-11-04
Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer
Oxaliplatin, Placebo, radiotherapy - Locally Advanced Rectal Cancer
Phase 3Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.5002026-11-252026-11-04
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
Irinotecan, Oxaliplatin, GFH276 - CRC
Phase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.1502026-11-152026-11-06
SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3)
Short-course radiotherapy, Long-course radiation, PD-1 antibody (Sintilimab) - Early Low Rectal Cancer
Phase 3Not yet recruitingFudan University3942026-11-152026-11-12
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)
Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms
Phase 4Not yet recruitingMerck Sharp & Dohme LLC1502026-11-062026-09-03
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] - Pancreatic Cancer, Borderline Resectable Pancreatic Cancer
Not applicableRecruitingIMGT Co., Ltd.3662026-11-042026-11-09
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC)
Phase 2Not yet recruitingSun Yat-sen University2292026-11-012026-10-16
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma
Iparomlimab and Tuvonralimab Injection (QL1706), Docetaxel, Oxaliplatin - Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2Not yet recruitingThe First Affiliated Hospital of Zhengzhou University342026-11-012026-09-18
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy
Phase 2Not yet recruitingTao Zhang1442026-11-012026-10-06
Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma
Glofitamab, Gemcitabine, Oxaliplatin - PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma
Phase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University402026-11-012026-10-22
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
DCSZ11, Radiation, Capecitabine - Rectal Cancer
Phase 2Not yet recruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins302026-11-012026-10-28
RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
RC118(Dose 1) plus RC148(Dose 1), RC118(Dose 1) plus RC148(Dose 2), RC118(Dose 2) plus RC148(Dose 1) - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2 / Phase 3Not yet recruitingRemeGen Co., Ltd.6802026-11-012026-11-13

Showing 20 of 1909. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (457)  ·  Stomach Neoplasms (307)  ·  Rectal Neoplasms (272)  ·  Colonic Neoplasms (192)  ·  Pancreatic Neoplasms (176)  ·  Neoplasm Metastasis (112)  ·  Esophageal Neoplasms (88)  ·  Neoplasms (71)  ·  Carcinoma, Hepatocellular (61)  ·  Adenocarcinoma Of Esophagus (55)  ·  Adenocarcinoma (50)  ·  Lymphoma, Large B-Cell, Diffuse (48)  ·  Cholangiocarcinoma (46)  ·  Carcinoma, Non-Small-Cell Lung (41)  ·  Biliary Tract Neoplasms (40)

Sponsors

National Cancer Institute (NCI) (65)  ·  Sun Yat-sen University (57)  ·  Fudan University (56)  ·  Hoffmann-La Roche (44)  ·  Sanofi (39)  ·  M.D. Anderson Cancer Center (32)  ·  Alliance for Clinical Trials in Oncology (27)  ·  UNICANCER (24)  ·  The First Affiliated Hospital with Nanjing Medical University (21)  ·  Merck Sharp & Dohme LLC (20)  ·  Fujian Cancer Hospital (19)  ·  Memorial Sloan Kettering Cancer Center (19)  ·  Eli Lilly and Company (18)  ·  GERCOR - Multidisciplinary Oncology Cooperative Group (18)  ·  Gruppo Oncologico del Nord-Ovest (14)

Countries

United States (688)  ·  China (583)  ·  France (180)  ·  South Korea (152)  ·  Germany (132)  ·  Italy (124)  ·  Spain (123)  ·  Canada (107)  ·  United Kingdom (104)  ·  Japan (100)  ·  Taiwan (83)  ·  Belgium (77)  ·  Australia (75)  ·  Poland (52)  ·  Brazil (50)

Top investigators

Project Leader (9)  ·  Norman Wolmark, MD (8)  ·  Alfredo Falcone, MD (5)  ·  Dae Young Zang, MD, PhD (5)  ·  Howard S. Hochster, MD (5)  ·  Jane Robertson (5)  ·  Jiren Yu (5)

Results publications

PMID 36306483, PMID 35623069, PMID 32816630, PMID 33356421, PMID 40341124, PMID 40812353, PMID 31268130, PMID 40340830, PMID 22226517, PMID 30679026, PMID 31378656, PMID 32085892, PMID 33439695, PMID 33538338, PMID 12049862, PMID 12540794, PMID 15908661, PMID 21444866, PMID 21561347, PMID 21831266, PMID 21997132, PMID 24901360, PMID 24982456, PMID 26187751, PMID 26861604, PMID 27275632, PMID 27986363, PMID 28006055, PMID 28237539, PMID 29471013, PMID 30566590, PMID 30982686, PMID 31070690, PMID 31557064, PMID 31765987, PMID 31811950, PMID 32418078, PMID 32939319, PMID 34905388, PMID 35594613, PMID 36525610, PMID 36940261, PMID 37678921, PMID 37963317, PMID 38315963, PMID 38347302, PMID 38564700, PMID 38861294, PMID 40373876, PMID 40680855

NIH funding

2023 (18), 2016 (17), 2018 (15), 2025 (13), 2015 (10), 2017 (10), P30CA033572 (8), U10CA021115 (8), U10CA032102 (8), P30CA043703 (7), U10CA180820 (7), U10CA180821 (7), 2009 (6), 2014 (6), U10CA180868 (6)